These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 38680542)

  • 1. High adherence to intermittent and continuous use of a contraceptive vaginal ring among women in a randomized controlled trial in Kigali, Rwanda.
    Kestelyn E; Van Nuil JI; Umulisa MM; Umutoni G; Uwingabire A; De Baetselier I; Uwineza M; Agaba S; Crucitti T; Delvaux T; van de Wijgert JHHM
    Front Glob Womens Health; 2024; 5():1278981. PubMed ID: 38680542
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomised trial of a contraceptive vaginal ring in women at risk of HIV infection in Rwanda: Safety of intermittent and continuous use.
    Kestelyn E; Agaba S; Van Nuil JI; Uwineza M; Umulisa MM; Mwambarangwe L; Ndagijimana JC; De Baetselier I; Buyze J; Delvaux T; Crucitti T; Jespers V; van de Wijgert JHHM;
    PLoS One; 2018; 13(6):e0197572. PubMed ID: 29856848
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High acceptability of a contraceptive vaginal ring among women in Kigali, Rwanda.
    Kestelyn E; Van Nuil JI; Umulisa MM; Umutoni G; Uwingabire A; Mwambarangwe L; Uwineza M; Agaba S; Crucitti T; van de Wijgert J; Delvaux T;
    PLoS One; 2018; 13(6):e0199096. PubMed ID: 29912906
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaginal probiotic adherence and acceptability in Rwandan women with high sexual risk participating in a pilot randomised controlled trial: a mixed-methods approach.
    Verwijs MC; Agaba S; Umulisa MM; Uwineza M; Nivoliez A; Lievens E; van de Wijgert JHHM
    BMJ Open; 2020 May; 10(5):e031819. PubMed ID: 32434932
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An open-label, randomized crossover study to evaluate the acceptability and preference for contraceptive options in female adolescents, 15 to 19 years of age in Cape Town, as a proxy for HIV prevention methods (UChoose).
    Gill K; Happel AU; Pidwell T; Mendelsohn A; Duyver M; Johnson L; Meyer L; Slack C; Strode A; Mendel E; Fynn L; Wallace M; Spiegel H; Jaspan H; Passmore JA; Hosek S; Smit D; Rinehart A; Bekker LG
    J Int AIDS Soc; 2020 Oct; 23(10):e25626. PubMed ID: 33034421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety, Acceptability and Adherence of Dapivirine Vaginal Ring in a Microbicide Clinical Trial Conducted in Multiple Countries in Sub-Saharan Africa.
    Nel A; Bekker LG; Bukusi E; Hellstrӧm E; Kotze P; Louw C; Martinson F; Masenga G; Montgomery E; Ndaba N; van der Straten A; van Niekerk N; Woodsong C
    PLoS One; 2016; 11(3):e0147743. PubMed ID: 26963505
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Contraceptive rings promote vaginal lactobacilli in a high bacterial vaginosis prevalence population: A randomised, open-label longitudinal study in Rwandan women.
    Crucitti T; Hardy L; van de Wijgert J; Agaba S; Buyze J; Kestelyn E; Delvaux T; Mwambarangwe L; De Baetselier I; Jespers V;
    PLoS One; 2018; 13(7):e0201003. PubMed ID: 30036385
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The ring plus project: safety and acceptability of vaginal rings that protect women from unintended pregnancy.
    Schurmans C; De Baetselier I; Kestelyn E; Jespers V; Delvaux T; Agaba SK; van Loen H; Menten J; van de Wijgert J; Crucitti T;
    BMC Public Health; 2015 Apr; 15():348. PubMed ID: 25880636
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Residual hormone levels in used contraceptive rings as a measurement of adherence to vaginal ring use.
    Haaland RE; Holder A; Evans-Strickfaden T; Nyagol B; Makanga M; Oyaro B; Humwa F; Williams T; McLellan-Lemal E; Desai M; Huey MJ
    Contraception; 2017 Jun; 95(6):602-604. PubMed ID: 28372978
    [TBL] [Abstract][Full Text] [Related]  

  • 10. "It's already in your body and it's preventing": a qualitative study of African female adolescent's acceptability and preferences for proxy HIV prevention methods in Cape Town, South Africa.
    Fynn L; Gill K; Wallace M; Atujuna M; Duyver M; Ngcobo P; Spiegel H; Rinehart A; Hosek S; Bekker LG
    BMC Public Health; 2023 Nov; 23(1):2143. PubMed ID: 37919697
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An interdisciplinary framework for measuring and supporting adherence in HIV prevention trials of ARV-based vaginal rings.
    MacQueen KM; Tolley EE; Owen DH; Amico KR; Morrow KM; Moench T; Friend DR; Friedland B
    J Int AIDS Soc; 2014; 17(3 Suppl 2):19158. PubMed ID: 25224617
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety of a silicone elastomer vaginal ring as potential microbicide delivery method in African women: A Phase 1 randomized trial.
    Nel A; Martins J; Bekker LG; Ramjee G; Masenga G; Rees H; van Niekerk N
    PLoS One; 2018; 13(5):e0196904. PubMed ID: 29813074
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vaginal Ring Use in a Phase 3 Microbicide Trial: A Comparison of Objective Measures and Self-reports of Non-adherence in ASPIRE.
    Mensch BS; Richardson BA; Husnik M; Brown ER; Kiweewa FM; Mayo AJ; Baeten JM; Palanee-Phillips T; van der Straten A;
    AIDS Behav; 2019 Feb; 23(2):504-512. PubMed ID: 30218318
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biomarkers and biometric measures of adherence to use of ARV-based vaginal rings.
    Stalter RM; Moench TR; MacQueen KM; Tolley EE; Owen DH;
    J Int AIDS Soc; 2016; 19(1):20746. PubMed ID: 27142091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Contraceptives for lactating women: a comparative trial of a progesterone-releasing vaginal ring and the copper T 380A IUD.
    Sivin I; Díaz S; Croxatto HB; Miranda P; Shaaban M; Sayed EH; Xiao B; Wu SC; Du M; Alvarez F; Brache V; Basnayake S; McCarthy T; Lacarra M; Mishell DR; Koetsawang S; Stern J; Jackanicz T
    Contraception; 1997 Apr; 55(4):225-32. PubMed ID: 9179454
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The ins and outs of drug-releasing vaginal rings: a literature review of expulsions and removals.
    Boyd P; Merkatz R; Variano B; Malcolm RK
    Expert Opin Drug Deliv; 2020 Nov; 17(11):1519-1540. PubMed ID: 32684013
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Skin patch and vaginal ring versus combined oral contraceptives for contraception.
    Lopez LM; Grimes DA; Gallo MF; Stockton LL; Schulz KF
    Cochrane Database Syst Rev; 2013 Apr; 2013(4):CD003552. PubMed ID: 23633314
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adherence and acceptability of the contraceptive ring compared with the pill among students: a randomized controlled trial.
    Gilliam ML; Neustadt A; Kozloski M; Mistretta S; Tilmon S; Godfrey E
    Obstet Gynecol; 2010 Mar; 115(3):503-510. PubMed ID: 20177280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety, adherence, and HIV-1 seroconversion among women using the dapivirine vaginal ring (DREAM): an open-label, extension study.
    Nel A; van Niekerk N; Van Baelen B; Malherbe M; Mans W; Carter A; Steytler J; van der Ryst E; Craig C; Louw C; Gwetu T; Mabude Z; Kotze P; Moraba R; Tempelman H; Gill K; Kusemererwa S; Bekker LG; Devlin B; Rosenberg Z;
    Lancet HIV; 2021 Feb; 8(2):e77-e86. PubMed ID: 33539761
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.